2-amino-N-(2,6-dimethylphenyl)propanamide

• ChemBase编号: 927
• 分子式: C11H16N2O
• 平均质量: 192.25754
• 单一同位素质量: 192.12626314
• SMILES: O=C(Nc1c(cccc1C)C)C(N)C
• Canonical SMILES: CC(C(=O)Nc1c(C)cccc1C)N
• InChI: InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)
• InChIKey: BUJAGSGYPOAWEI-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 2-amino-N-(2,6-dimethylphenyl)propanamide
• IUPAC传统名: tocainide
• 商标名: Tonocard
• 别名: Tocainida [INN-Spanish]; Tocainidum [INN-Latin]; Tocainide

登记号

• CAS号: 41708-72-9
• PubChem SID: 46505385; 160964390
• PubChem CID: 38945

理论计算性质

JChem

• Acid pKa: 13.653854
• 质子受体: 2
• 质子供体: 2
• LogD (pH = 5.5): -0.6713139
• LogD (pH = 7.4): 0.9973883
• Log P: 1.8824334
• 摩尔折射率: 58.857 cm^3
• 极化性: 22.107647 Å^3
• 极化表面积: 55.12 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.55
• LOG S: -2.08
• 溶解度: 1.60e+00 g/l

分子性质

理化性质

• 溶解度: 1.07E+004 mg/L
• 疏水性(logP): 1.1

详细说明

DrugBank - DB01056

• Drug Groups: approved
• Description: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of sodium channels. [PubChem]
• Indication: For the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
• Pharmacology: Tocainide is a primary amine analog of lidocaine with antiarrhythmic properties useful in the treatment of ventricular arrhythmias. Tocainide, like lidocaine, produces dose dependent decreases in sodium and potassium conductance, thereby decreasing the excitability of myocardial cells. In experimental animal models, the dose-related depression of sodium current is more pronounced in ischemic tissue than in normal tissue. Tocainide is a Class I antiarrhythmic compound with electrophysiologic properties in man similar to those of lidocaine, but dissimilar from quinidine, procainamide, and disopyramide.
• Toxicity: The oral LD₅₀ of tocainide was calculated to be about 800 mg/kg in mice, 1000 mg/kg in rats, and 230 mg/kg in guinea pigs; deaths were usually preceded by convulsions.
• Affected Organisms: Humans and other mammals
• Biotransformation: Negligible first pass hepatic degradation. No active metabolites have been found.
• Absorption: Following oral administration, the bioavailability approaches 100 percent, and is unaffected by food.
• Half Life: The average plasma half-life in patients is approximately 15 hours. May be prolonged up to 35 hours in patients with severe renal function impairment (creatinine clearance less than 30 mL per min per 1.73 square meters of body surface area.
• Protein Binding: Approximately 10 percent bound to plasma protein.
• External Links: Wikipedia; RxList; PDRhealth; Drugs.com